Bixiye
QP22-20 Pharmacy Benefit Exclusion for Tepezza TM
Taariikhda uu dhaqangalayo Barnaamijka: 12, Feb 2020
Natiijooyinka Raadinta
Soo bandhiga 2781 - 2790 ee natiijooyinka 4959
Bixiye
QP16-20 Pharmacy Benefit Exclusion for Padcev TM and Enhertu ®
Taariikhda uu dhaqangalayo Barnaamijka: 12, Feb 2020
Bixiye
QP21-20 Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Baclofen
Taariikhda uu dhaqangalayo Barnaamijka: 12, Feb 2020
Bixiye
QP18-20 Pharmacy Benefit Exclusion for Calcipotriene-Betamethasone Dipropionate Suspension 0.005-0.064% (authorized generic (AG) of Taclonex suspension)
Taariikhda uu dhaqangalayo Barnaamijka: 12, Feb 2020
Bixiye
P9-20 MHCP Prenatal Service Third Party Liability Change
Taariikhda uu dhaqangalayo Barnaamijka: 03, Feb 2020
Bixiye
P12-20 Updated Minnesota Health Care Programs and Minnesota Senior Health Options (MSHO) Prior Authorization and Medical Policy Requirements
Taariikhda uu dhaqangalayo Barnaamijka: 03, Feb 2020
Bixiye
P10-20 New Medical, Medical Drug and Behavioral Health Policy Management Updates – Effective April 6, 2020
Taariikhda uu dhaqangalayo Barnaamijka: 03, Feb 2020
Bixiye
P13-20 Medical Oncology Drug Prior Authorization Updates for Fully Insured Commercial and Medicare Advantage Subscribers- eviCore Healthcare Utilization Management (UM) Program
Taariikhda uu dhaqangalayo Barnaamijka: 03, Feb 2020
Bixiye
P11-20 Updated Bulletin: Commercial Inpatient Admission Notification Process Changes
Taariikhda uu dhaqangalayo Barnaamijka: 03, Feb 2020